NICE rebuffs Opdivo for non-squamous NSCLC

The U.K.'s NICE issued draft guidance recommending against PD-1 inhibitor Opdivo nivolumab from Bristol-Myers Squibb

Read the full 154 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE